Metabolic effects of once-a-month combined injectable contraceptives. The World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation, Geneva, Switzerland.
The results of metabolic studies on once-a-month combined injectable contraceptives are summarized, focusing on four preparations: dihydroxyprogesterone acetophenide 150 mg/estradiol enanthate 10 mg; depot-medroxyprogesterone acetate 25 mg/estradiol cypionate 5 mg; norethisterone enanthate 50 mg/estradiol valerate 5 mg; and 17 beta-hydroxyprogesterone caproate 250 mg/estradiol valerate 5 mg. Their effects on carbohydrate metabolism, lipid metabolism, hemostasis, serum prolactin, cortisol, binding globulins and liver functions are reviewed. Areas requiring further research are identified.
Giwa-Osagie
O F
OF
Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Nigeria.
D000077713:17 alpha-Hydroxyprogesterone Caproate; D000463:Algestone Acetophenide / Q000008:administration & dosage / Q000009:adverse effects; D050260:Carbohydrate Metabolism; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects*; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D006908:Hydroxyprogesterones / Q000008:administration & dosage / Q000009:adverse effects; D007267:Injections; D050356:Lipid Metabolism; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects; D009640:Norethindrone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
D003271:Contraceptive Agents, Female; D006908:Hydroxyprogesterones; D000077713:17 alpha-Hydroxyprogesterone Caproate; D004958:Estradiol; D017258:Medroxyprogesterone Acetate; C024319:norethindrone enanthate; D000463:Algestone Acetophenide; D009640:Norethindrone